Medibank results: Top line growth disappoints

Morgans Financial Limited

Morgans Financial Limited

Medibank's FY16 NPAT (A$418m) was 3% above consensus, driven by a strong Health Insurance (HI) operating profit of A$510m, ~8% above guidance (A$470m). FY16 HI top line growth was the result disappointment at 4% (guidance of 4.5-5%). FY17 outlook commentary was broad, without quantitative detail, pointing mainly to a continued tough top line environment and expected further normalising of claims utilisation rates. HI's cost performance has been highly impressive in our view. FY16 claims costs rose just 1%, while absolute HI management expenses were broadly flat. Overall MPL has delivered strong results since listing. While further cost out is a near-term theme, we feel that risks to HI profit margins are now tilting to the downside. We believe that if HI revenue growth isn’t restored, MPL could return to a mid-single digit EPS growth stock quickly when cost out ends. Keep reading for more detail, including the analyst rating: (VIEW LINK)


1 stock mentioned

Morgans Financial Limited
Stockbroker
Morgans Financial Limited

Morgans is Australia's largest national full-service retail stockbroking and wealth management network with over 240,000 client accounts, 500 authorised representatives and 950 employees operating from offices in all states and territories.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.